The WHO R&D Blueprint organized a consultation over two-days to discuss knowledge gaps and priority research questions for mpox (monkeypox) research.
During this forthcoming consultation global experts reviewed the available evidence in terms of:
- Our understanding the dynamics of monkeypox transmission and epidemiology and the clinical characteristics of the disease.
- Available evidence regarding therapeutics, diagnostics and vaccines licensed and under development.
- Novel approaches for evaluation of mpox therapeutics and vaccines.
- Country perspectives in terms of research priorities and opportunities.
PRESENTATIONS
Day 1: Thursday 2 June 2022
Session 1. Understanding the dynamics and epidemiology and the clinical characteristics of mpox
- Historical overview of monkeypox
- Global overview of current monkeypox epidemiology
- Current knowledge on monkeypox transmission dynamics
- Clinical aspects of monkeypox in DRC
- Monkeypox in Central African Republic
- Monkeypox in Nigeria: Epidemiology and response efforts
- Monkeypox in Nigeria : Epidemiology, surveillance, and laboratory capacity: what else is needed ?
- Monkeypox virus in wildlife
- A ONEHEALTH study of monkeypox human infection
- Monkeypox multi-country outbreak
- Monkeypox virus in Spain
- Monkeypox Incident: UKHSA Investigation of recent cases
- Social dimensions of monkeypox: gaps and priorities
- Overview of available diagnostics and those in the pipeline
- The challenge of sero-epidemiology for monkeypox
- The challenge of seroepidemiology: Research priorities and laboratory investigations
- Animal models of monkeypox infections
- Meeting summary
Day 2: Friday 3 June 2022
Session 2. Innovative approaches for evaluation of therapeutics
- Clinical characteristics of monkeypox – DRC experience
- Overview of available therapeutics, those in the pipeline, and approaches to evaluate their efficacy
- Design options for the evaluation of efficacy: advantages and disadvantages
- A cohort study of treatment outcomes in selected European countries
- Clinical trial to evaluate monkeypox treatments
- A clinician’s perspective on what additional data should be collected on the available therapeutics
- Overview of clinical management and infection control research priorities
Session 3. Innovative approaches for evaluation of vaccines
- Overview of available vaccines, those in the pipeline, and approaches to evaluate their efficacy
- WHO Core Protocol for monkeypox vaccines efficacy trials (also for control and containment)
- Vaccinating Against Monkeypox in the Democratic Republic of the Congo with JYNNEOS
- Design options for the evaluation of efficacy: advantages and disadvantages
- Meeting Summary
Learning materials available using the following links below
Monkeypox Outbreak Toolbox (who.int)
OpenWHO mpox introductory training:
Monkeypox: Introduction | OpenWHO
Variole du singe : Introduction | OpenWHO
OpenWHO mpox extended training:
Monkeypox epidemiology, preparedness and response | OpenWHO
Épidémiologie de la variole du singe, préparation et réponse| OpenWHO
WHO Advisory Committee for Variola virus Research (ACVVR) reports